HISUN(SH:600267) Ge Long Hui A P P·2026-01-06 11:57Group 1 - Company Zhejiang Borui Biopharmaceutical Co., Ltd. has submitted an application for an initial public offering (IPO) of overseas listed shares (H shares) to the Hong Kong Stock Exchange on January 6, 2026 [1] - Borui Biopharmaceutical is a leading biopharmaceutical company in China focused on immunotherapy, with integrated capabilities in research, production, and sales [2] - The company has developed a competitive portfolio of immunotherapy products, including the globally first-in-class IL-17A/F inhibitor Beijiele® and the first and only approved targeted CD20 innovative drug Anruixi® [2] Group 2 - Borui Biopharmaceutical has ranked first in the market share of biopharmaceuticals in the field of autoimmune diseases in China for two consecutive years since 2023, based on sales data [2] - The company holds a 39.62% stake in Borui Biopharmaceutical as of the date of the announcement [2]